The Study of Gemcitabine Plus Nab-Paclitaxel in Combination With Pegvorhyaluronidase Alfa (PVHA; PEGPH20) and Pembrolizumab as Front-line Treatment for Metastatic Pancreatic Adenocarcinoma.

• Status: Withdrawn
• Trial end date: 2021-07-31

Summary

This is an open-label single arm phase 2 study for patients with metastatic pancreatic ductal adenocarcinoma who have not received any prior systemic therapies.

• Phase: Phase 2

Details

• Lead Sponsor: Yale University
• Treatments: Albumin-Bound Paclitaxel; Gemcitabine; Paclitaxel; Pembrolizumab